Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
12.21
-0.20 (-1.61%)
At close: Aug 1, 2025, 4:00 PM
12.80
+0.59 (4.83%)
After-hours: Aug 1, 2025, 7:51 PM EDT
Accolade Revenue
Septerna had revenue of $219.00K in the quarter ending March 31, 2025, a decrease of -30.91%. This brings the company's revenue in the last twelve months to $977.00K, up 108.76% year-over-year. In the year 2024, Septerna had annual revenue of $1.08M with 611.92% growth.
Revenue (ttm)
$977.00K
Revenue Growth
+108.76%
P/S Ratio
253.92
Revenue / Employee
$13,027
Employees
75
Market Cap
544.06M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.08M | 924.00K | 611.92% |
Dec 31, 2023 | 151.00K | - | - |
Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSEPN News
- 5 weeks ago - Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside - Benzinga
- 2 months ago - Septerna to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist - Seeking Alpha
- 2 months ago - Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash - Seeking Alpha
- 2 months ago - Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga
- 2 months ago - Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases - WSJ
- 2 months ago - Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - Reuters